79669-90-2

Basic information

• Product Name: 11-HYDROXY-6,11-DIHYDRO-DIBENZO[B,E]OXEPINE-2-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 11-HYDROXY-6,11-DIHYDRO-DIBENZO[B,E]OXEPINE-2-CARBOXYLIC ACID METHYL ESTER;METHYL 11-HYDROXY-6,11-DIHYDRODIBENZO[B,E]OXEPINE-2-CARBOXYLATE
• CAS NO: 79669-90-2
• Molecular Formula: C₁₆H₁₄O₄
• Molecular Weight: 270.28
• Mol File: 79669-90-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 11-HYDROXY-6,11-DIHYDRO-DIBENZO[B,E]OXEPINE-2-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 11-HYDROXY-6,11-DIHYDRO-DIBENZO[B,E]OXEPINE-2-CARBOXYLIC ACID METHYL ESTER(79669-90-2)
• EPA Substance Registry System: 11-HYDROXY-6,11-DIHYDRO-DIBENZO[B,E]OXEPINE-2-CARBOXYLIC ACID METHYL ESTER(79669-90-2)

Safety Data

• Hazardous Substances Data: 79669-90-2(Hazardous Substances Data)

Usage

General Description

11-HYDROXY-6,11-DIHYDRO-DIBENZO[B,E]OXEPINE-2-CARBOXYLIC ACID METHYL ESTER, also known as clozapine N-oxide (CCNO), is a chemical compound that has been used in the research of schizophrenia and other psychiatric disorders. 11-HYDROXY-6,11-DIHYDRO-DIBENZO[B,E]OXEPINE-2-CARBOXYLIC ACID METHYL ESTER is a derivative of clozapine, an antipsychotic medication, and has been studied for its potential therapeutic effects on the central nervous system. CCNO is known to interact with several neurotransmitter systems in the brain, including dopamine and serotonin receptors, which are believed to play a role in the development of psychiatric conditions. Research on CCNO is ongoing, and it may hold promise as a potential treatment for certain psychiatric disorders in the future.

Upstream product

• 79669-87-7 methyl 11-oxo-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate 

Downstream Products

• 188607-35-4 Methyl 11-[4-hydroxy-4-(3-trifluoromethylphenyl)piperidine-1-yl]-6,11-dihydrodibenzo[b,e] oxepine-2-carboxylate 
• 127167-15-1 Methyl 11-[2-[(2-hydroxy)phenyl]ethyl]oxy-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate 
• 188607-23-0 Methyl 11-(4-hydroxy-4-phenylpiperidine-1-yl)-6,11-dihydrodibenzo[b,e] oxepine-2-carboxylate 
• 142437-44-3 (-)-11-<<2-<(styrylsulfonyl)amino>ethyl>thio>-6,11-dihydrodibenzoxepin-2-carboxylic acid (trimethylsilyl)ethyl ester 
• 142437-45-4 (+)-11-<<2-<(styrylsulfonyl)amino>ethyl>thio>-6,11-dihydrodibenzoxepin-2-carboxylic acid (trimethylsilyl)ethyl ester 
• 142423-39-0 (-)-11-<<2-<(styrylsulfonyl)amino>ethyl>thio>-6,11-dihydrodibenzoxepin-2-carboxylic acid 
• 142423-38-9 (+)-11-<<2-<(styrylsulfonyl)amino>ethyl>thio>-6,11-dihydrodibenzoxepin-2-carboxylic acid 
• 123226-57-3 (+/-)-11-<<2-<(styrylsulfonyl)amino>ethyl>thio>-6,11-dihydrodibenzoxepin-2-carboxylic acid 
• 123226-46-0 11-[2-[(Phenylsulfonyl)amino]ethyl]thio-6, 11-dihydrodibenz-[b,e]oxepin-2-carboxylic acid 
• 142423-99-2 11-[2-(3-Nitro-benzenesulfonylamino)-ethylsulfanyl]-6,11-dihydro-dibenzo[b,e]oxepine-2-carboxylic acid methyl ester 
• 142424-00-8 11-[2-(4-Nitro-benzenesulfonylamino)-ethylsulfanyl]-6,11-dihydro-dibenzo[b,e]oxepine-2-carboxylic acid methyl ester 
• 142424-01-9 11-[2-(4-Trifluoromethyl-benzenesulfonylamino)-ethylsulfanyl]-6,11-dihydro-dibenzo[b,e]oxepine-2-carboxylic acid methyl ester 
• 142423-98-1 11-[2-(2-Nitro-benzenesulfonylamino)-ethylsulfanyl]-6,11-dihydro-dibenzo[b,e]oxepine-2-carboxylic acid methyl ester 
• 142424-07-5 11-[2-(2,5-Dimethoxy-benzenesulfonylamino)-ethylsulfanyl]-6,11-dihydro-dibenzo[b,e]oxepine-2-carboxylic acid methyl ester 

Relevant articles and documents

Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1

A series of 11-[[2-[(arylsulfonyl)amino]ethyl]thio]-6,11- dihydrodibenz[b,e]oxepin-2-carboxylic acids and related derivatives were synthesized. The compounds were tested for their antagonizing effects on guinea pig platelet TXA2/PGH2 receptors. Structure-activity relationships are discussed. (±)-11-[[2-[(Styrylsulfonyl)amino]ethyl]thio]-6,11- dihydrodibenz[b,e]oxepin-2-carboxylic acid (41) and (±)-11-[[2- [(phenylsulfonyl)amino]ethyl]thio]-6,11-dihydrodibenz[b,e]thiepin-2- carboxylic acid (4af) were the most promising compounds with K(i) values of 6.5 ± 0.29 and 3.7 ± 0.31 nM, respectively, for the TXA2/PGH2 receptor. These compounds also significantly inhibited U-46619-induced guinea pig platelet aggregation ex vivo (10 mg/kg po). Compound 41 was resolved into its optically active form. The (-)-isomer was 60-fold more potent than the (+)- isomer in the TXA2/PGH2 receptor binding assay. Some compounds tested in this study showed both TXA2/PGH2 receptor antagonizing and TXA2 synthase inhibitory effects.

A new series of antiallergic agents. I. Synthesis and activity of 11-(2-aminoethyl)thio-6,11-dihydrodibenz[b,e]oxepin derivatives

A new series of 11-substituted 6,11-dihydrodibenz[b,e]oxepin derivatives was synthesized and evaluated for antiallergic activity. Convenient methods for the preparation of sulfides from alcohols were developed. Structure-activity relationships are described. Compound 7, 11-[2-(dimethylamino)ethyl]thio-6,11-dihydrodibenz[b,e]oxepin-2-carboxy lic acid hydrochloride, was the most potent in the rat passive cutaneous anaphylaxis test (ED50 = 0.92 mg/kg p.o.). It had a potent inhibitory effect on anaphylactic bronchoconstriction in guinea pigs (ED50 = 0.029 mg/kg p.o.) and H1 receptor antagonistic effect (K(i) = 14 nM) with few central nervous system side effects. Additionally, an antagonistic effect against prostagrandin D2-induced contraction of isolated guinea pig trachea (pA2 = 5.73) was an attractive mechanism of action of the new antiallergic agent. Compound 7 was selected for further evaluation as KW-4994.

Dibenz[b,e]oxepin compounds

Novel dibenz[b,e]oxepin derivatives are employed in the treatment and control of allergic conditions such as allergic asthma.